WA
NBIX icon

Waddell & Associates’s Neurocrine Biosciences NBIX Stock Holding History

Waddell & Associates’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$763K Sell
4,525
-440
-9% -$65.3K 0.04% 169
2026
Q1 		$654K Buy
4,965
+1,720
+53% +$228K 0.04% 174
2025
Q4 		$460K Buy
3,245
+1,024
+46% +$148K 0.03% 191
2025
Q3 		$312K Buy
+2,221
New +$301K 0.03% 205

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PBBUPS
PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
AB
Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return

Waddell & Associates's NBIX Position: Q2 2026 in Review

Waddell & Associates reduced its Neurocrine Biosciences (NBIX) stake by 8.9% in Q2 2026, selling an estimated $65.3K and leaving 4,525 shares worth $763K. The position accounts for 0.04% of the portfolio, ranked #169.

Waddell & Associates first reported a position in NBIX in Q3 2025 and has held it in 4 quarters since. 198 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Waddell & Associates held 4,525 shares of Neurocrine Biosciences worth $763K as of Q2 2026.
  • Waddell & Associates sold 440 Neurocrine Biosciences shares in Q2 2026, an estimated $65.3K.
  • Neurocrine Biosciences made up 0.04% of Waddell & Associates's portfolio in Q2 2026, its #169 holding.
  • Waddell & Associates first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 4 quarters since.
  • 198 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Waddell & Associates's 13F filing for Q2 2026, filed 15 Jul 2026.